Navitoclax + Ruxolitinib + Celecoxib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasm
Conditions
Myeloproliferative Neoplasm
Trial Timeline
Nov 8, 2019 → Dec 31, 2026
NCT ID
NCT04041050About Navitoclax + Ruxolitinib + Celecoxib
Navitoclax + Ruxolitinib + Celecoxib is a phase 1 stage product being developed by AbbVie for Myeloproliferative Neoplasm. The current trial status is active. This product is registered under clinical trial identifier NCT04041050. Target conditions include Myeloproliferative Neoplasm.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04041050 | Phase 1 | Active |
Competing Products
20 competing products in Myeloproliferative Neoplasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| AUY922 | Novartis | Phase 2 | 52 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 49 |
| INCA036978 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 49 |
| Ruxolitinib + Lenalidomide + Prednisone | Incyte | Phase 2 | 49 |
| itacitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 74 |
| INCB160058 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Pemigatinib | Incyte | Phase 2 | 49 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 49 |
| INCA035784 | Incyte | Phase 1 | 30 |